Výsledky vyhledávání - "Mohit Trikha"

Abstract 6392: Combination of pulsed electric field, immunotherapy and cisplatin significantly prolongs survival in an orthotopic breast cancer mouse model

Autor: Chiara Pastori, Mukta Wagh, Ebtesam Nafie, Fatima Murad, Mohit Trikha, Robert Neal

Publikováno v: Cancer Research. 83:6392-6392

Introduction: Pulsed Electric Field (PEF) therapy is a novel approach to treat cancer by providing focal tumor ablation while sparing sensitive structures within the tumor micro-environment. Previous studies have demonstrated that PEF induces immunog

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::514fe740b3501ec8a22b1c194d54e77a
https://doi.org/10.1158/1538-7445.am2023-6392

Zobrazit plný text záznamu

Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data

Autor: Warren P. Mason, Santosh Kesari, Mohit Trikha, Nancy Levin, Benjamin Winograd, Daniela A. Bota, Steven D. Reich, Ileana Elias, Annick Desjardins, Rajiv Magge

Publikováno v: Neuro-Oncology Advances, vol 3, iss 1
Neuro-oncology Advances

Background This phase I/II trial in patients with recurrent glioblastoma (GBM) evaluates the safety and preliminary efficacy of marizomib, an irreversible pan-proteasome inhibitor that crosses the blood–brain barrier. Methods Part A assessed the sa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9490a4a3e9c8b7548c8dc0d5acfdb9ce
https://doi.org/10.1093/noajnl/vdab142

Zobrazit plný text záznamu

First in Human Study of an on/Off Switchable CAR-T Cell Platform Targeting CD19 for B Cell Malignancies (CLBR001 + SWI019)

Autor: Jing Li, Rakhee Vaidya, Travis S. Young, Carolyn Mulroney, Ian W. Flinn, Jonathan Strauss, Vadim Klyushnichenko, Koen van Besien, Peter A. Riedell, Eduardo Laborda, Jose C. Cruz, Liana Nikolaenko, Mohit Trikha, Peter G. Schultz, Michael Emde

Publikováno v: Blood. 138:2822-2822

BACKGROUND: CD19 targeted chimeric antigen receptor (CAR) T cells are a transformative treatment option for patients with relapsed, refractory B cell malignancies. Despite remarkable responses in heavily pretreated patients, challenges remain related

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::954fe3fb62edb5dc0cd58666d5dabaee
https://doi.org/10.1182/blood-2021-151727

Zobrazit plný text záznamu

A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results

Autor: Paul G. Richardson, Amit Khot, Jeffrey A. Zonder, Steven D. Reich, Ann MacLaren, Jacob P. Laubach, Ashraf Z. Badros, Dharminder Chauhan, Todd M. Zimmerman, Simon J. Harrison, Nancy Levin, Krystal Bergin, Andrew Spencer, Mohit Trikha

Publikováno v: British Journal of Haematology. 180:41-51

Marizomib (MRZ) is an irreversible, pan-subunit proteasome inhibitor (PI) in clinical development for relapsed/refractory multiple myeloma (RRMM) and glioma. This study analysed MRZ, pomalidomide (POM) and low-dose dexamethasone (Lo-DEX) [PMD] in RRM

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4f346ac8896a6ee3b1f7c8b6df47689
https://doi.org/10.1111/bjh.14987

Zobrazit plný text záznamu

Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results

Autor: Steven D. Reich, Mohit Trikha, Andrew Spencer, Paul N. Mainwaring, Simon J. Harrison, Timothy J. Price, Peeter Padrik, Craig Underhill, Michael Millward, Paul Cannell

Publikováno v: Clinical Cancer Research. 22:4559-4566

Purpose: Marizomib (NPI-0052) is an irreversible proteasome inhibitor, derived from a marine actinomycete, with activity and specificity that is distinct from other proteasome inhibitors. Experimental Design: Phase I study (NPI-0052-102) evaluated th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::216ee9fb54a1599dfcc3bff567d0adce
https://doi.org/10.1158/1078-0432.ccr-15-2616

Zobrazit plný text záznamu

Nanoparticle Formulation Derived from Carboxymethyl Cellulose, Polyethylene Glycol, and Cabazitaxel for Chemotherapy Delivery to the Brain

Autor: Mark J. Ernsting, Joseph Bteich, Kenneth K. Sokoll, Mohammed Mohammed, Henry B. Lowman, Trevor D. McKee, Mohit Trikha, Taira Kiyota

Publikováno v: Bioconjugate chemistry. 29(6)

Nanoparticles provide a unique opportunity to explore the benefits of selective distribution and release of cancer therapeutics at sites of disease through varying particle sizes and compositions that exploit the enhanced permeability of tumor-associ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fcdb04e45a38edd875b8231132f875d
https://pubmed.ncbi.nlm.nih.gov/29734804

Zobrazit plný text záznamu

Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD®immunomodulatory drug pomalidomide

Autor: Paul G. Richardson, Deepika Sharma Das, Arghya Ray, Dharminder Chauhan, Kenneth C. Anderson, Mohit Trikha, Yan Song

Publikováno v: British Journal of Haematology. 171:798-812

The proteasome inhibitor bortezomib is an effective therapy for the treatment of relapsed and refractory multiple myeloma (RRMM); however, prolonged treatment can be associated with toxicity, peripheral neuropathy and drug resistance. Our earlier stu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d066289b038f99bb64c1c4e3c17ab78
https://doi.org/10.1111/bjh.13780

Zobrazit plný text záznamu

ACTR-71. FULL ENROLLMENT RESULTS FROM THE PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) ± BEVACIZUMAB (BEV) IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, RGBM)

Autor: Nancy Levin, Steven D. Reich, Benjamin Winograd, Mohit Trikha, Daniela A. Bota, Rajiv Magge, Annick Desjardins, Santosh Kesari, Warren P. Mason

Publikováno v: Neuro-Oncology, vol 19, iss suppl_6
Neuro-oncology, vol 19, iss Suppl 6

MRZ – an irreversible, brain-penetrant, pan-proteasome inhibitor with anti-glioma preclinical activity – was evaluated in BEV-naïve rGBM patients. METHODS Phase 1 (P1) MRZ+BEV, 3+3 MRZ dose-escalation (N=6, 3, 3 at 0.55, 0.7, 0.8mg/m2) followed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed8bd5c1f568ee72798db5d99cf7c75c
https://escholarship.org/uc/item/3bj5x8wt

Zobrazit plný text záznamu

Marizomib for central nervous system-multiple myeloma

Autor: Zeba Singh, Paul G. Richardson, Mohit Trikha, Ann MacLaren, Young Kwok, Ashraf Z. Badros, Parameswaran Hari, Binod Dhakal

Publikováno v: British journal of haematology. 177(2)

Summary Marizomib, a natural marine product, is an irreversible proteasome inhibitor currently under investigation in relapsed-refractory multiple myeloma (RRMM) and malignant glioma. Central nervous system-multiple myeloma (CNS-MM) is a rare manifes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45a37831d21f1f5c59c6d1ed6b044d46
https://pubmed.ncbi.nlm.nih.gov/28387460

Zobrazit plný text záznamu

Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier

Autor: Kaijun Di, Vivek Abraham, Ann MacLaren, Daniela A. Bota, Francis Burrows, Mohit Trikha, Annick Desjardins, G. Kenneth Lloyd

Publikováno v: Di, K; Lloyd, GK; Abraham, V; MacLaren, A; Burrows, FJ; Desjardins, A; et al.(2016). Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier. NEURO-ONCOLOGY, 18(6), 840-848. doi: 10.1093/neuonc/nov299. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/3td7095n
Neuro-oncology, vol 18, iss 6

Author(s): Di, Kaijun; Lloyd, G Kenneth; Abraham, Vivek; MacLaren, Ann; Burrows, Francis J; Desjardins, Annick; Trikha, Mohit; Bota, Daniela A | Abstract: BackgroundThe proteasome plays a vital role in the physiology of glioblastoma (GBM), and protea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::189cad27274943aad25e5e0de0d7bc38
http://www.escholarship.org/uc/item/3td7095n

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání